China Medical System H1 FY26 profit rises 4.3% to RMB 971.5 million; revenue climbs 12.5% to RMB 4.5 billion

• China Medical System posted turnover up 12.5% to RMB 4.5 billion for the six months ended June 30, 2026.
• Profit for the period rose 4.3% to RMB 971.5 million; basic earnings per share increased 4.7% to RMB 0.4075.
• Innovative and exclusive products revenue climbed 19.7% to RMB 1.7 billion, lifting their turnover share by 2.2 percentage points to 37.7%.
• Interim dividend was set at RMB 0.1634 per share, up 5.1%; 6,400,000 shares were repurchased for about HK$ 67.9 million.
• Three innovative drugs were launched in China, while five innovative drugs covering six indications were under NDA review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12287475), on August 17, 2026, and is solely responsible for the information contained therein.